Saturday 17 October 2026
Export NXGL’s income statement to Excel — free account
NexGel, Inc.
NXGL Healthcare Medical Instruments & Supplies
NexGel, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.4 million, up 31.5% from fiscal 2024. In the quarter to June 2026, revenue grew 27.8%, EPS fell 344.4%, free cash flow fell 432.3% and total debt rose 353.8%, each against the same quarter a year earlier. Dividend growth for three consecutive years, revenue growth for five.
5.59
0.41
+7.92%
Follow NXGL
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
7.48 | 9.22 | 22.14 | 33.34 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(41.11) | (206.08) | 900.00 | (495.52) | |
P/B ratio |
16.52 | 23.17 | 51.71 | 69.76 | |
Price to Tangible BV |
0.00 | 38.48 | 82.06 | 104.12 | |
EV/Sales |
7.66 | 9.22 | 22.12 | 33.26 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(28.83) | (73.38) | (192.72) | (158.30) | |
EV/FCF |
(27.68) | (69.59) | (174.49) | (151.50) | |
Quick Ratio |
0.19 | 0.84 | 0.59 | 0.82 | |
Current Ratio |
0.43 | 1.70 | 1.47 | 1.69 | |
Net Debt/EBITDA |
5.23 | 0.16 | 0.40 | 1.49 | |
Debt/Assets |
13.97% | 17.25% | 6.99% | 6.66% | |
Debt/Equity |
0.68 | 0.45 | 0.15 | 0.14 | |
Asset Turnover |
0.67 | 1.02 | 1.07 | 1.05 | |
Operating CF/Net income |
0.60 | 0.54 | (0.29) | 1.20 | |
Capex/Depreciation |
(0.03) | (0.05) | (0.10) | 2.67 | |
Interest Coverage |
— | (22.81) | (52.78) | 72.50 | |
Research and Development Expense of Revenue |
0.54% | 0.00% | (0.21%) | 0.24% | |
Selling, General and Administrative Expense of Revenue |
97.50% | 76.19% | 72.94% | 66.84% | |
Intangible Assets out of Total Assets |
0.55 | 0.15 | 0.17 | 0.16 | |
Share Based Compensation of Revenue |
3.23% | 5.40% | 5.58% | 6.99% | |
Graham Net Nets |
(0.16) | (0.01) | 0.00 | 0.00 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(7.09%) | (3.16%) | (1.18%) | (0.76%) | |
Free Cash Flow Yield |
(3.70%) | (1.44%) | (0.57%) | (0.66%) | |
Revenue per Share |
0.41 | 0.32 | 0.36 | 0.37 | |
Operating CF per Share |
(0.24) | (0.06) | 0.04 | (0.10) | |
Capex per Share |
(0.01) | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.25) | (0.06) | 0.03 | (0.10) | |
Cash per Share |
0.19 | 0.26 | 0.13 | 0.23 | |
Shareholders Equity per Share |
0.61 | 0.55 | 0.62 | 0.70 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.61 | 0.55 | 0.62 | 0.70 | |
Free Cash Flow |
(2.27) | (0.51) | 0.24 | (0.79) | |
Working Capital |
(8.27) | 2.32 | 1.38 | 2.29 | |
Capital Expenditures |
(0.08) | (0.01) | (0.04) | (0.01) | |
Net Current Asset Value |
(14.81) | (1.48) | (1.23) | (0.44) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.00 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.92 | 0.79 | 0.80 | 0.87 | |
Average Payables |
2.60 | 1.64 | 1.29 | 1.36 | |
Average Inventory |
2.06 | 2.05 | 1.93 | 1.90 | |
Average Assets |
18.08 | 11.02 | 10.72 | 11.10 | |
Average Common Equity |
5.26 | 5.03 | 5.49 | 5.28 |
Columns are period end dates